A rapid NT-proBNP cardiac biomarker test to manage HF
Used in conjunction with clinical assessment, the new Triage NT-proBNP (N-terminal pro b-type natriuretic peptide) test is a useful biomarker in the diagnosis and management of patients with heart failure (HF) its manufacturer Alere International reports.
‘BNP (b-type natriuretic peptide) and NT-proBNP levels can help doctors differentiate between HF and other problems, since the level of natriuretic peptides in the blood increases as chronic heart failure advances.’
In addition to a diagnosis in cases of suspected HF, the firm adds that the new test can also aid in assessing the risk of patients with heart failure, or acute coronary syndrome (ACS), or the increased risk for cardiovascular events and mortality in patients with stable coronary artery disease (CAD) who are also at risk of HF.
The Alere Triage NT-proBNP Test is CE marked for EU distribution.
03.11.2010
More on the subject:
